ClinicalTrials.gg
RecruitingNCT05543447REhealUpdated Sep 4, 2025

DERIVO® 2heal® Study: Clinical Safety and Efficacy of the DERIVO® 2heal® Embolisation Device

An observational study in Intracranial Aneurysm and Flow Diverter, sponsored by Acandis GmbH. Recruiting at 17 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-04.

Sponsored by Acandis GmbH · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Dec 2022; still recruiting 3 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
158
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 46 studies in Intracranial Aneurysm with a site in Germany — 9 open to participants now, 14 under way, none of them phase 3. Intracranial Aneurysm · Germany.

Planned enrollment
20th of 32
158 · median 206
Started
2022
with 1 other
Observational
33 of 46
8 open now
Primary completion
2025-12
later than 4 of 13 live
Registered
42nd of 46
by date
Lead sponsor
2 of 46
Acandis GmbH

Among the 46 studies in Intracranial Aneurysm with a site in Germany, this one is the 20th largest by planned enrollment of the 32 observational ones that give a count, is one of 2 that started in 2022, is one of 33 observational ones, reaches primary completion later than 4 of the 13 other live ones, and was the 42nd registered.

Intracranial Aneurysm

419 studies on the registry are indexed under Intracranial Aneurysm; 118 are open to participants now.

Browse Intracranial Aneurysm studies →

Open to participants now

9 of the 46 studies in Intracranial Aneurysm with a site in Germany are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 84 Intracranial Aneurysm studies recruiting now, 50 (60%) set no upper age limit and 15 (18%) stop at 75 or younger; 16 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Intracranial Aneurysm with a site in Germany, or all of them as a file.
02

Study summary

To analyse the clinical safety and efficacy of the DERIVO® 2heal® Embolisation Device in the standard clinical routine of flow diversion treatment with respect to the mid- and long-term clinical and angiographic outcomes.

Read the detailed description

The purpose of the DERIVO® 2heal® trial is to conduct a post market clinical follow-up (PMCF) study of the use of the DERIVO® 2heal® Embolisation Device in clinical practice according to EU MDCGs guidance. The DERIVO® 2heal® Study is designed as a prospective, single-arm, multicenter, open-label, national study conducted in Germany with approximately 15 sites planned. The study aims to investigate potential residual risks associated with the use of the device and to update the clinical evaluation of the device in order to ensure the long-term safety and performance of the DERIVO® 2heal® Embolisation Device after its placing on the market. For this purpose, the DERIVO® 2heal® Study will systematically collect information on technical success, safety, and clinical success of treatment of intracranial aneurysms with DERIVO® 2heal® Embolisation Device in clinical practice.

The study duration is expected to be 36 months of enrolment and 12 months follow-up of patients. Up to 158 patients should be enroled at approx. 15 study sites in Germany.

Informed consent will be obtained from all patients prior to implantation of the DERIVO® 2heal® Embolisation Device. In exceptional cases, informed consent may be obtained after the intervention, as the study is purely data collection. It should be noted that the signed informed consent form must be obtained before recording of data in the study and prior any study-specific assessments. Informed consent process will be performed according to ICH-GCP standards. In case of emergency situations when the treatment needs to be performed immediately and informed consent cannot be given prior to the rescue treatment, the informed consent can be obtained retrospectively from the patient or patient's legal representative.

The analysis population will be consist of all patients enrolled who were treated with DERIVO® 2heal® Embolisation device or in whom an attempt of DERIVO® 2heal® Embolisation device implantation was made.

Personal data will be processed in accordance with the relevant national and international legislation and good clinical practice. Data will only be processed for the purpose of the PMCF study. Person-identifiable data will not leave the unit from which they originated, and for pseudonymized data, keys to identification numbers will be held confidentially by the responsible person. Individual patient's medical information will be recorded in the study only in pseudonymized form.

All data in this project are captured in eCRFs and stored into an electronic clinical database. Quality control and data validation procedures such as programmed automatic edit and consistency checks ensure data validity and accuracy immediately at the point of entry into this database. The database application which is used to capture electronic clinical trial data is protected from unauthorized access it is, among other features, access restricted, contains rights and roles functionalities, provides electronic authentication of data entries, maintains an electronic audit trail and provides appropriate data backup functionalities.

After data entry, study monitoring team will perform source data verification and issue monitoring queries directly in the database application.

The database will only be locked after all queries and discrepancies that may have occurred during data entry have been resolved. After database lock, data will be exported in an electronic format and transferred to the responsible biometrician for analysis. The locked database may also be used to generate subject listings and tabulations.

The results of the trial will be reported to the central Ethics Committees after the study was completed. By signing the protocol, the investigator agrees that the results of the clinical investigation may be used for publication. The investigator also agrees that is not permitted to publish any data related to the trial independent of the Sponsor.

03

Conditions studied

  • Intracranial Aneurysm
  • Flow Diverter

Keywords

  • Aneurysm
  • DERIVO
  • DERIVO 2 Heal
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients who were selected for flow diversion therapy and will be treated with DERIVO® 2heal® Embolisation Device due to intracranial aneurysm according to clinical routine.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient to be treated with DERIVO® 2heal® Embolisation Device due to intracranial aneurysm according to IFU
  • Age > 18 years
  • Signed Form
  • Patient scheduled to be treated for only one target aneurysm except multiple aneurysms located in the same target zone to be treated with one DERIVO® 2heal® Embolisation Device
  • Effective use of antiplatelet medication confirmed by applicable testing method according to local standard

Exclusion criteria

Exclusion Criteria:

  • Previously treated aneurysms with flow diverter, stent or WEB device
  • Treatment as preparation for the flow-diversion treatment does not lead to exclusion of the patient
  • Patient with a ruptured aneurysm in the acute phase of bleeding
  • Pre-treatment disability (mRS > 2)
  • Aneurysms related to pre-existing arteriosclerotic vascular disease in the target vessel
  • against treatment with anti- medication
  • Female patient who is known to be pregnant or is breastfeeding or wishes to become pregnant during participation in the study
  • Participating in another study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
158 participants (estimated)
Patient registry
No

Interventions

  • DeviceFlow Diverter Treatment with DERIVO 2 Heal Embolisation Device

    Flow diversion therapy fpr intracranial aneurysm treatment.

06

What researchers measure

Primary outcomes

  1. Primary efficacy endpoint

    • Rate of complete aneurysm occlusion

    Time frame: 6 weeks +/- 3weeks; 6months +/- 3 months; 12months +/-3months

  2. Primary safety endpoint

    * Stroke/Death Occurrence Percentage of subjects with major stroke in the territory of treated artery or neurological death post-procedure * Rate of device-related \& procedure-related complications (e.g. ICH, in-stent stenosis, in-stent thrombosis)

    Time frame: 12month ± 3month

  3. Primary clinical endpoint

    • Good Clinical outcome

    Time frame: 6 weeks ± 3weeks; 6months ± 3 months; 12months ± 3months

Secondary outcomes

  1. Secondary efficacy endpoint

    * Wall apposition of the flow-diverter(s) per patient as determined by the treating physician and the core-lab after treatment. 1. Correct wall apposition in the parent vessel 2. Gap between FD and vessel wall \< 25 % of vessel diameter 3. Gap between FD and vessel wall \>25 % of vessel diameter * Stasis / flow changes in the aneurysm (O´Kelly Marotta Scale/Kamran grading scale)

    Time frame: Measured directly after treatment

  2. Secondary safety endpoint

    • Rate of participants (%) with significant parent artery stenosis (\> 50%) or retreatment of the target aneurysm post-procedure

    Time frame: 12months ± 3months

07

Study locations

17 of 17 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for Dec 2025, 36 months after the start.

Of 105 observational studies under Intracranial Aneurysm, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 145. This study's planned 36 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2022
First posted
Sep 16, 2022
StartActual
Dec 15, 2022
Primary completionEst.
Dec 2025
CompletionEst.
Dec 2026
Last update
Sep 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05543447
Lead sponsor
Acandis GmbH
Responsible party
Sponsor
First posted
Sep 16, 2022
Start date
Dec 15, 2022
Primary completion
Dec 2025 (estimated)
Completion
Dec 2026 (estimated)
Last update
Sep 4, 2025

Study contacts

Acandis GmbH
Contact
info@acandis.com
Tel: +49 7231 155 00 0
Behme Daniel, Prof.
study director · Universitätsklinikum Magdeburg

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion